InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $15.920 0.07 (0.44%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$5,418 Notification of cessation of securities - TLX 5 Oct 2026 8:23AM $15.160 $15.920 risen by 5.01%
$5,418 Notification regarding unquoted securities - TLX 5 Oct 2026 8:22AM $15.160 $15.920 risen by 5.01%
$5,418 Application for quotation of securities - TLX 5 Oct 2026 8:22AM $15.160 $15.920 risen by 5.01%
$5,418 FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging 30 Sep 2026 8:20AM $16.150 $15.920 fallen by 1.42%
$5,418 Change in substantial holding 25 Sep 2026 6:06PM $15.900 $15.920 risen by 0.13%
$5,418 Appendix 3Y Change in Director Interest-D Gill 25 Sep 2026 3:31PM $15.940 $15.920 fallen by 0.13%
$5,418 Application for quotation of securities - TLX 25 Sep 2026 3:17PM $15.910 $15.920 risen by 0.06%
$5,418 Grant of waivers of Listing Rule 7.3.4 22 Sep 2026 8:24AM $15.760 $15.920 risen by 1.02%
$5,418 Telix and ITM Join Forces to Create Radiopharma Powerhouse 21 Sep 2026 8:38AM $17.850 $15.920 fallen by 10.81%
$5,418 Telix and ITM Join Forces to Create Radiopharma Powerhouse 21 Sep 2026 8:37AM $17.850 $15.920 fallen by 10.81%
$5,418 Application for quotation of securities - TLX 14 Sep 2026 4:41PM $16.340 $15.920 fallen by 2.57%
$5,418 FDA Approves Telix Brain Cancer Imaging Drug Pixclara 14 Sep 2026 8:21AM $15.670 $15.920 risen by 1.60%
$5,418 Telix Completes Enrollment in Phase 3 BiPASS Study 2 Sep 2026 8:16AM $15.270 $15.920 risen by 4.26%
$5,418 Telix Appoints David Gill as Chair 1 Sep 2026 8:18AM $15.360 $15.920 risen by 3.65%
$5,418 Telix HY26 Results Presentation 20 Aug 2026 8:42AM $16.840 $15.920 fallen by 5.46%
$5,418 Telix HY26 Results Announcement 20 Aug 2026 8:41AM $16.840 $15.920 fallen by 5.46%
$5,418 Telix HY26 Appendix 4D and Interim Report 20 Aug 2026 8:40AM $16.840 $15.920 fallen by 5.46%
$5,418 Telix H1 2026 Results - Investor Webcast Notification 31 Jul 2026 8:30AM $14.070 $15.920 risen by 13.15%
$5,418 Change in substantial holding 24 Jul 2026 8:21AM $15.170 $15.920 risen by 4.94%
$5,418 Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress 21 Jul 2026 8:26AM $15.100 $15.920 risen by 5.43%
$5,418 Notification of cessation of securities - TLX 10 Jul 2026 8:24AM $16.940 $15.920 fallen by 6.02%
$5,418 Notification regarding unquoted securities - TLX 10 Jul 2026 8:24AM $16.940 $15.920 fallen by 6.02%
$5,418 Application for quotation of securities - TLX 10 Jul 2026 8:24AM $16.940 $15.920 fallen by 6.02%
$5,418 Change in substantial holding 8 Jul 2026 5:49PM $16.580 $15.920 fallen by 3.98%
$5,418 Ceasing to be a substantial holder 3 Jul 2026 1:36PM $16.710 $15.920 fallen by 4.73%

1 - 25 of 965 results

Page 1 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.